ARGX - Argenx gains after setback to Roche/Chugai myasthenia gravis therapy
2024-03-21 07:00:09 ET
More on Argenx SE
- argenx SE (ARGX) Q4 2023 Earnings Call Transcript
- argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion
- Argenx SE GAAP EPS of -$1.68 misses by $0.30, revenue of $374M beats by $10.28M
- Argenx SE Q4 2023 Earnings Preview
- Seeking Alpha’s Quant Rating on Argenx SE